RayzeBio, Inc.
Clinical trials sponsored by RayzeBio, Inc., explained in plain language.
Biotech developing radiopharmaceutical therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New scan could reveal hidden kidney cancer Results expected Dec 2026 (estimated)
- New radioactive drug aims to fight gut tumors that resist standard therapy Results expected Dec 2026 (estimated)
- Radioactive drug takes aim at Hard-to-Treat tumors Results expected Feb 2027 (estimated)
- New imaging tracer could spot hidden cancers Results expected Jul 2027 (estimated)
- New combo therapy targets tough lung cancer in early trial Results expected Jul 2027 (estimated)
-
Radioactive drug takes aim at Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase trial tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The drug delivers a powerful radioactive particle directly to cancer cells. The study aims to find the safe…
Phase 1 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New dynamic duo targets Hard-to-Treat liver cancer
Disease control Recruiting nowThis study tests two new drugs: one to help spot liver cancer cells (RYZ811) and another to deliver treatment directly to them (RYZ801). It is for people with a type of liver cancer called GPC3-positive hepatocellular carcinoma that cannot be removed by surgery. The goal is to se…
Phase 1/2 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New radioactive drug aims to fight gut tumors that resist standard therapy
Disease control Recruiting nowThis study tests a new drug called RYZ101 in people with advanced neuroendocrine tumors (GEP-NETs) that have grown after prior radiation therapy. The trial has two parts: first finding the right dose, then comparing RYZ101 to standard treatments like everolimus or sunitinib. Abou…
Phase 3 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC